A Phase 1 interventional study of AZD1390 in Advanced Solid Malignancies, sponsored by AstraZeneca. Not yet recruiting at 2 sites in United Kingdom. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase I, multicentre, single-dose, open-label study to assess the absorption, distribution, metabolism, and excretion of [14C]-AZD1390.
On Day 1, participants will receive one dose of [14C]-AZD1390 . Participants will be confined to the study site until Day 8.
Approximately 8 enrolled male and female participants will receive study intervention in order to achieve a minimum of 4 evaluable participants.
Participants in this study will contribute to essential knowledge that will support the development of AZD1390 as a potential treatment for GBM, a malignancy of high unmet need, while being exposed to a low level of immediate risk.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's planned enrollment of 8 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of \[14C\]-AZD1390
Drug: AZD1390
single dose
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
Amount excreted (Ae) (urine)
Time frame: 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
Cumulative Amount excreted (CumAe) (urine)
Time frame: 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
Amount excreted (Ae) (feaces)
Time frame: 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
Cumulative Amount excreted (CumAe) (feaces)
Time frame: 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
Amount excreted (Ae) (total - urine and feaces combined)
Time frame: 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
Cumulative Amount excreted (CumAe) (total urine and feaces combined)
Time frame: 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
Amount (percentage) excreted (Fe) (urine)
Time frame: 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
Cumulative Amount (percentage) excreted (CumFe) (urine)
Time frame: 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
Amount (percentage) excreted (Fe) (feaces)
Time frame: 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
Cumulative Amount (percentage) excreted (CumAe) (feaces)
Time frame: 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
Amount (percentage) excreted (Fe) (total urine and faeces combined)
Time frame: 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
Cumulative Amount (percentage) excreted (CumFe) (total urine and faeces combined)
Time frame: 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
If emesis occurs, vomitus will be analysed for total radioactivity
Time frame: 6 Weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Analysis of plasma: Maximum observed concentration (Cmax)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Analysis whole blood: Maximum observed concentration (Cmax)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Analysis of plasma: Area under the concentration-time curve from zero to infinity (AUCinf)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Analysis of whole blood: Area under the concentration-time curve from zero to infinity (AUCinf)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Analysis of plasma: Area under the concentration-time curve from zero to the last measurable concentration (AUClast)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Analysis of whole blood: Area under the concentration-time curve from zero to the last measurable concentration (AUClast)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Analysis of plasma: Time to reach maximum observed plasma concentration (Tmax)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Analysis of whole blood: Time to reach maximum observed plasma concentration (Tmax)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Analysis of plasma: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz )
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Analysis of whole blood: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz )
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Analysis of plasma: Apparent total body clearance of drug from plasma after extravascular administration (CL/F)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Analysis of whole blood: Apparent total body clearance of drug from plasma after extravascular administration (CL/F)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Analysis of plasma: Mean residence time of the unchanged drug in the systemic circulation (MRT)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Analysis of whole blood: Mean residence time of the unchanged drug in the systemic circulation (MRT)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Analysis of plasma: Apparent volume of distribution at steady state following extravascular administration (Vss/F)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Analysis of whole blood: Apparent volume of distribution at steady state following extravascular administration (Vss/F)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Analysis of plasma: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Analysis of whole blood: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Ratio of AUCinf of plasma AZD1390 relative to AUCinf of plasma total radioactivity
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
Ratio of AUCinf of whole blood total radioactivity to AUCinf of plasma total radioactivity
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 after a single oral dose
Analysis of urine: Cumulative amount excreted (CumAe)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 after a single oral dose
Analysis of urine: Fraction (percentage) excreted (Fe)
Time frame: 6 weeks
The distribution of total radioactivity into blood cells after a single oral dose
Analysis of urine: Fraction (percentage) excreted (Fe)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 after a single oral dose
Analysis of urine: Cumulative fraction (percentage) excreted (CumFe)
Time frame: 6 weeks
Pharmacokinetic(s) of AZD1390 after a single oral dose
Analysis of urine: Renal clearance (CLR)
Time frame: 6 weeks
The phamrmacokinetic(s) of AZD1390 metabolite
Analysis of plasma: Maximum observed concentration (Cmax)
Time frame: 6 weeks
The phamrmacokinetic(s) of AZD1390 metabolite
Analysis of plasma: Area under the concentration-time curve from zero to infinity (AUCinf)
Time frame: 6 weeks
The phamrmacokinetic(s) of AZD1390 metabolite
Analysis of plasma: Area under the concentration-time curve from zero to the last measurable concentration (AUClast)
Time frame: 6 weeks
The phamrmacokinetic(s) of AZD1390 metabolite
Analysis of plasma: Time to reach maximum observed plasma concentration (Tmax)
Time frame: 6 weeks
The phamrmacokinetic(s) of AZD1390 metabolite
Analysis of plasma: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz )
Time frame: 6 weeks
The phamrmacokinetic(s) of AZD1390 metabolite
Analysis of plasma: Apparent total body clearance of drug from plasma after extravascular administration (CL/F)
Time frame: 6 weeks
The phamrmacokinetic(s) of AZD1390 metabolite
Analysis of plasma: Apparent volume of distribution at steady state following extravascular administration (Vss/F)
Time frame: 6 weeks
The phamrmacokinetic(s) of AZD1390 metabolite
Analysis of plasma: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)
Time frame: 6 weeks
The phamrmacokinetic(s) of AZD1390 metabolite
Analysis of metabolite in plasma: parent ratio
Time frame: 6 weeks
Metabolic profiling following single oral dose of AZD1390
Quantification and identification of major metabolites of AZD1390 in plasma and excreta.
Time frame: 6 weeks
The safety of a single dose of AZD1390
Number of participants with AEs and SAEs and severity of AEs and SAEs (based on CTCAE v5).
Time frame: 6 weeks
The safety of a single dose of AZD1390
Number of participants with laboratory abnormalities based on assessment of Haematology/Haemostasis (whole blood), Urinalysis (dipstick), Serology, Clinical chemistry (serum or plasma), Creatinine clearance.
Time frame: 6 weeks
The safety of a single dose of AZD1390
Number of participants with abnormal ECG and measurement of heart rate, PR QRS, QT and QTcF intervals (in milliseconds)
Time frame: 6 weeks
The safety of a single dose of AZD1390
Number of participants with abnormal vital signs based on assessment of body temperature, pulse rate, and blood pressure completed with automated devices.
Time frame: 6 weeks
The safety of a single dose of AZD1390
Assessment of weight (measurement units can be variable) throughout the study.
Time frame: 6 weeks
The safety of a single dose of AZD1390
Number of participants with abnormal physical examination based on assessment of general appearance, respiratory, cardiovascular, abdomen, skin, head and neck, lymph nodes, thyroid, musculoskeletal, and neurological systems.
Time frame: 6 weeks
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Apr 2028, 21 months later.
Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's planned 21 months is below that.
Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD1390